More articles from Epigenetic Cancer Therapies

Abstract B42: Decitabine specifically targets genes that gain DNA methylation and lose expression in cancer and can be combined with histone methylation inhibitors for increased efficacy
Takahiro Sato, Matteo Cesaroni, Anthony Tran, Jozef Madzo, Yasuyuki Okamoto, Hanghang Zhang, Shoghag Panjarian, Jaroslav Jelinek, Jean-Pierre Issa

Cancer Research Jan 2016, 76 (2 Supplement) B42; DOI: 10.1158/1538-7445.CHROMEPI15-B42
Abstract IA27: Tazemetostat, an EZH2 inhibitor and potential therapeutic for non-Hodgkin lymphoma
Jesse J. Smith

Cancer Research Jan 2016, 76 (2 Supplement) IA27; DOI: 10.1158/1538-7445.CHROMEPI15-IA27
Abstract B39: BRD4 inhibition improves the efficacy of ABT-199 in T-cell acute lymphoblastic leukemia
Sofie Peirs, Filip Matthijssens, Tim Pieters, Niels Vandamme, Geert Berx, Bruce Poppe, Pieter Van Vlierberghe

Cancer Research Jan 2016, 76 (2 Supplement) B39; DOI: 10.1158/1538-7445.CHROMEPI15-B39
Abstract PR10: A DNA hypomethylation signature predicts novel antitumor activity of LSD1 inhibition in SCLC
Helai Mohammad, Ryan Kruger

Cancer Research Jan 2016, 76 (2 Supplement) PR10; DOI: 10.1158/1538-7445.CHROMEPI15-PR10
Abstract B40: WEE1 inhibition selectively kills histone H3K36me3-deficient cancers by dNTP starvation
Sophia X. Pfister, Enni Markkanen, Yanyan Jiang, Sovan Sarkar, Mick Woodcock, Lykourgos-Panagiotis Zalmas, Giulia Orlando, Neele Drobnitzky, Grigory Dianov, Songmin Ying, Nicholas B. La Thangue, Vincenzo D'Angiolella, Anderson Ryan, Timothy C. Humphrey

Cancer Research Jan 2016, 76 (2 Supplement) B40; DOI: 10.1158/1538-7445.CHROMEPI15-B40
Abstract IA23: Multiple targetable pathways for epigenetic therapy
Jean-Pierre J. Issa

Cancer Research Jan 2016, 76 (2 Supplement) IA23; DOI: 10.1158/1538-7445.CHROMEPI15-IA23
Abstract B51: The pan deacetylase inhibitor panobinostat shows cytotoxic activity as monotherapy and synergism with topoisomerase inhibitors in cervical cancer cells
Lubna Wasim, Madhu Chopra

Cancer Research Jan 2016, 76 (2 Supplement) B51; DOI: 10.1158/1538-7445.CHROMEPI15-B51
Abstract B30: Targeting EZH2 methyltransferase activity: A novel therapeutic approach to ARID1A-deficient cancer
Benjamin Bitler, Azat Garipov, Ie Ming Shih, Rugang Zhang

Cancer Research Jan 2016, 76 (2 Supplement) B30; DOI: 10.1158/1538-7445.CHROMEPI15-B30
Abstract B50: A phenotypic screen to identify novel potential epigenetic anticancer drugs from natural compounds
Hanghang Zhang, Noël J.-M Raynal, Takahiro Sato, Yasuyuki Okamoto, Benjamin Garcia, George Morton, Wayne Childers, Marlene A. Jacobson, Stephen B. Baylin, Magid Abou-Gharbia, Jean-Pierre J. Issa

Cancer Research Jan 2016, 76 (2 Supplement) B50; DOI: 10.1158/1538-7445.CHROMEPI15-B50
Abstract B43: Dose and context-dependent roles for Arid1a in liver tumorigenesis
Xuxu Sun, Sam Wang, Liem Nguyen, Hao Zhu

Cancer Research Jan 2016, 76 (2 Supplement) B43; DOI: 10.1158/1538-7445.CHROMEPI15-B43

Main menu

User menu

Search

More articles from Epigenetic Cancer Therapies

Pages

Articles

Info for

About Cancer Research